Scientists test new pill cocktails in fight against tough cancers
NCT ID NCT02208375
Summary
This early-stage trial is testing the safety and best doses of two different combinations of oral medications for people with recurrent endometrial, ovarian, or triple-negative breast cancer. The study combines an existing drug (olaparib) with one of two newer drugs (AZD2014 or AZD5363) to see if they work better together to stop cancer growth. The main goal is to find the safest, most effective dose for each combination before larger studies.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT FALLOPIAN TUBE CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.